Total Payments
$5,519
2020 Payments
$74.86
Companies
8
Transactions
24
Medicare Patients
18,992
Medicare Billing
$51.7M
Payment Breakdown by Category
Consulting$3,000 (54.4%)
Travel$1,376 (24.9%)
Research$794.10 (14.4%)
Food & Beverage$324.11 (5.9%)
Education$25.40 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $3,000 | 1 | 54.4% |
| Travel and Lodging | $1,376 | 3 | 24.9% |
| Unspecified | $794.10 | 8 | 14.4% |
| Food and Beverage | $324.11 | 10 | 5.9% |
| Education | $25.40 | 2 | 0.5% |
Payments by Type
General
$4,725
16 transactions
Research
$794.10
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences Inc | $4,593 | 7 | $0 (2017) |
| ViiV Healthcare Company | $794.10 | 8 | $0 (2017) |
| Amgen Inc. | $30.49 | 2 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $27.31 | 2 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $25.40 | 2 | $0 (2020) |
| Genentech USA, Inc. | $18.11 | 1 | $0 (2020) |
| AbbVie, Inc. | $16.93 | 1 | $0 (2019) |
| Lundbeck LLC | $13.56 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $74.86 | 5 | Amgen Inc. ($30.49) |
| 2019 | $56.94 | 4 | AstraZeneca Pharmaceuticals LP ($27.31) |
| 2017 | $5,387 | 15 | Gilead Sciences Inc ($4,593) |
All Payment Transactions
24 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/25/2020 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: Bone Health | ||||||
| 05/19/2020 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $13.56 | General |
| Category: NEUROLOGY | ||||||
| 05/05/2020 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $18.11 | General |
| Category: Immunology | ||||||
| 04/21/2020 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $13.36 | General |
| Category: Bone Health | ||||||
| 01/13/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/23/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/12/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $16.93 | General |
| Category: Virology | ||||||
| 07/30/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/28/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $12.76 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/19/2017 | ViiV Healthcare Company | — | — | Cash or cash equivalent | $407.06 | Research |
| Study: Ph 3 HIV two year non inferiority compared to standard of care safety tolerability acceptability of long acting injectable regimen | ||||||
| 01/19/2017 | ViiV Healthcare Company | — | — | Cash or cash equivalent | $108.41 | Research |
| Study: Ph 3 HIV two year non inferiority compared to standard of care safety tolerability acceptability of long acting injectable regimen | ||||||
| 01/19/2017 | ViiV Healthcare Company | — | — | Cash or cash equivalent | $69.34 | Research |
| Study: Ph 3 HIV two year non inferiority compared to standard of care safety tolerability acceptability of long acting injectable regimen | ||||||
| 01/19/2017 | ViiV Healthcare Company | — | — | Cash or cash equivalent | $58.21 | Research |
| Study: Ph 3 HIV two year non inferiority compared to standard of care safety tolerability acceptability of long acting injectable regimen | ||||||
| 01/19/2017 | ViiV Healthcare Company | — | — | Cash or cash equivalent | $53.33 | Research |
| Study: Ph 3 HIV two year non inferiority compared to standard of care safety tolerability acceptability of long acting injectable regimen | ||||||
| 01/19/2017 | ViiV Healthcare Company | — | — | Cash or cash equivalent | $51.81 | Research |
| Study: Ph 3 HIV two year non inferiority compared to standard of care safety tolerability acceptability of long acting injectable regimen | ||||||
| 01/19/2017 | ViiV Healthcare Company | — | — | Cash or cash equivalent | $24.24 | Research |
| Study: Ph 3 HIV two year non inferiority compared to standard of care safety tolerability acceptability of long acting injectable regimen | ||||||
| 01/19/2017 | ViiV Healthcare Company | — | — | Cash or cash equivalent | $21.70 | Research |
| Study: Ph 3 HIV two year non inferiority compared to standard of care safety tolerability acceptability of long acting injectable regimen | ||||||
| 01/13/2017 | Gilead Sciences Inc | Epclusa (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: HCV | ||||||
| 01/13/2017 | Gilead Sciences Inc | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $873.20 | General |
| Category: HCV | ||||||
| 01/13/2017 | Gilead Sciences Inc | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $282.38 | General |
| Category: HCV | ||||||
| 01/13/2017 | Gilead Sciences Inc | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $220.00 | General |
| Category: HCV | ||||||
| 01/13/2017 | Gilead Sciences Inc | Epclusa (Drug) | Food and Beverage | In-kind items and services | $124.96 | General |
| Category: HCV | ||||||
| 01/13/2017 | Gilead Sciences Inc | Epclusa (Drug) | Food and Beverage | In-kind items and services | $49.93 | General |
| Category: HCV | ||||||
| 01/13/2017 | Gilead Sciences Inc | Epclusa (Drug) | Food and Beverage | In-kind items and services | $42.82 | General |
| Category: HCV | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Ph 3 HIV two year non inferiority compared to standard of care safety tolerability acceptability of long acting injectable regimen | ViiV Healthcare Company | $794.10 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 40 | 5,122 | 1,081,020 | $32.5M | $15.9M |
| 2022 | 40 | 4,795 | 933,384 | $28.4M | $14.0M |
| 2021 | 40 | 5,157 | 939,220 | $29.0M | $14.9M |
| 2020 | 39 | 3,918 | 511,877 | $13.7M | $6.9M |
Total Patients
18,992
Total Services
3,465,501
Medicare Billing
$51.7M
Procedure Codes
159
All Medicare Procedures & Services
159 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 1,121 | 115,560 | $3.4M | $2.1M | 61.1% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 68 | 115,200 | $3.6M | $1.9M | 54.5% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2023 | 68 | 51,840 | $2.5M | $1.6M | 61.5% |
| J3245 | Injection, tildrakizumab, 1 mg | Office | 2023 | 33 | 12,200 | $2.0M | $1.3M | 65.7% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2023 | 26 | 25,200 | $1.9M | $1.1M | 58.8% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2023 | 54 | 8,280 | $1.8M | $1.1M | 58.5% |
| J2182 | Injection, mepolizumab, 1 mg | Office | 2023 | 31 | 36,900 | $1.5M | $847,849 | 58.3% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 32 | 22,525 | $1.4M | $749,826 | 52.9% |
| J0485 | Injection, belatacept, 1 mg | Office | 2023 | 50 | 240,048 | $1.1M | $690,944 | 62.5% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 93 | 26,039 | $3.7M | $654,344 | 17.9% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 59 | 76,860 | $803,183 | $606,585 | 75.5% |
| J2356 | Injection, tezepelumab-ekko, 1 mg | Office | 2023 | 27 | 41,160 | $854,482 | $591,411 | 69.2% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 56 | 52,158 | $2.5M | $548,135 | 21.9% |
| J9312 | Injection, rituximab, 10 mg | Office | 2023 | 26 | 7,300 | $842,749 | $429,503 | 51.0% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 20 | 12,120 | $1.1M | $428,549 | 37.5% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 19 | 77,105 | $570,851 | $358,118 | 62.7% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 18 | 89,600 | $1.4M | $349,437 | 25.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 442 | 2,545 | $324,880 | $125,005 | 38.5% |
| J1306 | Injection, inclisiran, 1 mg | Office | 2023 | 25 | 11,360 | $156,196 | $106,436 | 68.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 184 | 814 | $285,863 | $77,630 | 27.2% |
| J3032 | Injection, eptinezumab-jjmr, 1 mg | Office | 2023 | 14 | 5,700 | $110,591 | $76,594 | 69.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 1,356 | 5,388 | $215,520 | $59,329 | 27.5% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 72 | 741 | $111,150 | $41,240 | 37.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 127 | 322 | $44,114 | $18,945 | 42.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 154 | 886 | $71,060 | $18,309 | 25.8% |
About Dr. Robert Brennan, MD
Dr. Robert Brennan, MD is a Infectious Disease healthcare provider based in Lynchburg, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1659355170.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Brennan, MD has received a total of $5,519 in payments from pharmaceutical and medical device companies, with $74.86 received in 2020. These payments were reported across 24 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($3,000).
As a Medicare-enrolled provider, Brennan has provided services to 18,992 Medicare beneficiaries, totaling 3,465,501 services with total Medicare billing of $51.7M. Data is available for 4 years (2020–2023), covering 159 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Internal Medicine
- Location Lynchburg, VA
- Active Since 11/30/2005
- Last Updated 04/24/2025
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1659355170
Products in Payments
- Epclusa (Drug) $4,593
- EVENITY (Biological) $30.49
- FARXIGA (Drug) $27.31
- ZERBAXA (Drug) $25.40
- Xolair (Biological) $18.11
- Mavyret (Drug) $16.93
- VYEPTI (Biological) $13.56
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.